Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 12/20 | 0.60 |
| ▸ | CDK8 | P49336 | 2/20 | 0.51 |
| ▸ | KDR | P35968 | 4/20 | 0.48 |
| ▸ | BRAF | P15056 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA7 | P43166 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL938360 | 0.92 | RAF1 (0.62) | RAF1CDK8KDRBRAF | |
| SCHEMBL936932 | 0.78 | RAF1 (0.64) | RAF1CDK8KDRBRAFCA7 | |
| SCHEMBL13556629 | 0.75 | RAF1 (0.72) | RAF1CDK8KDRBRAFCA1 | |
| SCHEMBL16628075 | 0.75 | RAF1 (0.67) | RAF1CDK8KDRBRAFCA1 | |
| SCHEMBL13524681 | 0.74 | RAF1 (0.74) | RAF1CDK8KDRBRAFCA7 | |
| SCHEMBL13529088 | 0.73 | RAF1 (0.70) | RAF1CDK8KDRBRAFCA7 | |
| SCHEMBL16621336 | 0.73 | RAF1 (0.84) | RAF1CDK8KDRBRAF | |
| SCHEMBL6014335 | 0.73 | RAF1 (0.79) | RAF1CDK8KDR | |
| SCHEMBL937747 | 0.73 | RAF1 (0.69) | RAF1CDK8KDRBRAFCA7 | |
| SCHEMBL19668099 | 0.71 | RAF1 (0.80) | RAF1CDK8KDRBRAFCA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2324825-A1 | Aryl ureas with angiogenesis inhibiting activity | Bayer Healthcare LLC (US) | 2011-05-25 | — | — | EP | claimed |
| EP-1478358-B1 | Sorafenib tosylate for the treatment of diseases characterized by abnormal angiogenesis | BAYER HEALTHCARE LLC (US) | 2013-07-03 | — | — | EP | disclosed |
| EP-1636585-B2 | DIARYL UREAS WITH KINASE INHIBITING ACTIVITY | BAYER HEALTHCARE LLC (US) | 2012-06-13 | — | — | EP | disclosed |
| EP-2324825-A1 | Aryl ureas with angiogenesis inhibiting activity | Bayer Healthcare LLC (US) | 2011-05-25 | — | — | EP | disclosed |
| EP-2289515-A2 | Combinations comprising a diaryl urea and an interferon | Bayer HealthCare LLC (US) | 2011-03-02 | — | — | EP | disclosed |
| US-20110015195-A1 | ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY | DUMAS JACQUES | 2011-01-20 | — | — | US | disclosed |
| US-7838541-B2 | Aryl ureas with angiogenesis inhibiting activity | BAYER HEALTHCARE, LLC (US) | 2010-11-23 | — | — | US | disclosed |
| EP-1636585-B1 | DIARYL UREAS WITH KINASE INHIBITING ACTIVITY | BAYER PHARMACEUTICALS CORP (US) | 2008-01-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015195-A1 | ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY | FLT1, FLT4, KDR | RAF1 867/4885CDK8 125/4885KDR 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.